Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
Three IPOs and two SPACs priced this week, and two SPACs submitted filings. City Therapeutics (CTY) priced its upsized IPO at the midpoint to raise $200 million at a $1.0 billion market cap. City Therapeutics is a Phase 1 biotech developing RNA interference...read more
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, raised $150 million by offering 9.4 million shares at $16, within the $15 to $17 range. Existing shareholder ARK Investment Management and new investor...read more
While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two more on the calendar for the week ahead. RNA interference biotech City Therapeutics (CTY) plans to raise $175 million at a $1.0 billion...read more
Renaissance Capital’s October IPO Market Update
Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more
US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week’s pricings
Three IPOs and two SPACs priced this week, and two SPACs submitted filings. City Therapeutics (CTY) priced its upsized IPO at the midpoint to raise $200 million at a $1.0 billion market cap. City Therapeutics is a Phase 1 biotech developing RNA interference...read more
Small molecule biotech Iambic Therapeutics prices IPO at $16, the midpoint of the range
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, raised $150 million by offering 9.4 million shares at $16, within the $15 to $17 range. Existing shareholder ARK Investment Management and new investor...read more
US IPO Week Ahead: Biotech remains a bright spot in a 2 IPO week
While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two more on the calendar for the week ahead. RNA interference biotech City Therapeutics (CTY) plans to raise $175 million at a $1.0 billion...read more